Market News & Trends
Vaxart Announces Selection of its Oral COVID-19 Vaccine Lead Candidate
Vaxart, Inc. recently announced it has selected its lead COVID-19 vaccine candidate and has contracted with KindredBio to manufacture bulk vaccine under cGMP to complement…
Apollomics Announces Initiation of SPARTA Phase 2 Clinical Trial
Apollomics, Inc. recent announced the initiation of the Phase 2 portion of the Phase 1/2 clinical trial for APL-101 based on completion of the Phase 1 and approval from the….
FDA Approves Octapharma USA Investigational New Drug Application for Severe COVID-19 Patients
The US FDA has recently approved the investigational new drug (IND) application submitted by Octapharma USA for a Phase 3 clinical trial on…
SeraNovo Enters Second License Agreement With Carna Biosciences
SeraNovo B.V. recently announced it has signed a second License Agreement with Carna Biosciences, Inc., a company engaged in the drug development of….
CanSino Biologics & Precision NanoSystems Announce Collaboration to Co-Develop a COVID-19 RNA Vaccine
CanSino Biologics Inc. and Precision NanoSystems (PNI) recently announced a co-development agreement of a mRNA lipid nanoparticle (mRNA-LNP) vaccine against COVID-19. The parties will…
CureVac´s Optimized mRNA Platform Provides Positive PreClinical Results at Low Dose for COVID-19 Vaccine Candidate
CureVac AG recently announced positive preclinical results at a low dose for its lead vaccine candidate against the novel Coronavirus (SARS-CoV-2). The data showed a…
Almac Discovery Enters Into Licensing Agreement for the Development & Commercialization of ALM301
Almac Discovery, a member of the Almac Group, recently announced an out-licensing partnership with an undisclosed biotechnology company in order to advance the development and…
Cue Biopharma Announces Strategic Research Collaboration
Cue Biopharma, Inc. recently announced it has entered into a research collaboration agreement with Dr. Michael Dustin and the University of Oxford to determine the…
Triphase Accelerator & Catalent Announce Interim Results of a Dose Escalation Phase 1 Clinical Trial
Triphase Accelerator and Catalent recently announced interim results for Triphase Accelerator's multi-center, open-label, monotherapy study of TRPH-222 in heavily pre-treated patients with relapsed and/or refractory…
ChemoCentryx & VFMCRP Announce Topline Data from Phase 2 LUMINA-1 Trial
ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) recently announced topline data from a 46-patient Phase 2 dose-ranging trial in the orphan kidney…
Krystal Biotech Announces Positive Interim Results from Phase 1/2 Clinical Trial
Krystal Biotech, Inc. recently announced interim results for a first-in-human Phase 1/2 placebo controlled clinical trial evaluating topical administration of KB105 in patients with autosomal…
MD Anderson & Innovent Biologics Announce Strategic Rare Cancer Development Collaboration
The University of Texas MD Anderson Cancer Center and Innovent Biologics, Inc. recently announced a strategic collaboration agreement to co-develop TYVYT (sintilimab injection), Innovent’s anti-PD-1 monoclonal…
Taconic Biosciences Launches Rapid Restart Program
Taconic Biosciences, a global leader in providing drug discovery animal model solutions, recently announced the successful implementation of its Rapid Restart program….
COVID-19’s Effect Will Boost Infectious Disease Drug Approvals & Present Opportunities to CMOs
In response to the global pandemic, biopharma companies have put a renewed emphasis on finding treatments for infectious diseases, including COVID-19 and other infectious diseases overall…..
Akers Biosciences & Premas Biotech Announce Successful Completion of COVID-19 Vaccine Prototype & Obtained First Images of VLP
Akers Biosciences, Inc. recently announced that Premas Biotech, its partner in the development of a vaccine candidate that is seeking to address the COVID-19 pandemic…..
Santhera Signs Agreements in Gene Therapy Research With Rutgers University
Santhera Pharmaceuticals recently announced the signing of two agreements with Rutgers, The State University of New Jersey as part of its program to advance gene…
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial
Rubius Therapeutics, Inc. recently announced that the first patient has been dosed in its Phase 1/2 clinical trial of RTX-240 for the treatment of patients…
Catalent Partners With Humanigen to Support FDA-Approved Phase 3 Lenzilumab Study for COVID-19
Catalent recently welcomed the news by Humanigen, Inc., that it has dosed the first COVID-19 patient in its previously announced Phase 3 study for lenzilumab,…
Yourway & Firma Clinical Research Collaborate to Administer Coordinated Supply Delivery for Home-Health Clinical Trial Visits
Yourway, an integrated premium courier and clinical packager in the global clinical trials supply chain market, and Firma Clinical Research, the niche service provider for…
Evelo Biosciences, Rutgers University & Robert Wood Johnson University Hospital Announce Submission of IND for Phase 2 Study of EDP1815 in COVID-19 Patients
Evelo Biosciences, Inc., Rutgers University, and Robert Wood Johnson University Hospital recently announced the submission of an Investigational New Drug (IND) application for an Evelo-sponsored…
